Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

41.27
+0.82002.03%
Post-market: 41.270.00000.00%18:39 EDT
Volume:1.26M
Turnover:52.12M
Market Cap:1.06B
PE:- -
High:41.37
Open:40.60
Low:40.60
Close:40.45
52wk High:43.52
52wk Low:28.77
Shares:25.80M
Float Shares:25.80M
Volume Ratio:15.04
T/O Rate:4.90%
Dividend:0.29
Dividend Rate:0.71%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

AbbVie Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
8 hours ago

U.S. Stocks on the MOVE -VF Corp, Biogen, AbbVie

Reuters
·
11 hours ago

Sector Update: Healthcare

MT Newswires Live
·
11 hours ago

Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand

MT Newswires Live
·
12 hours ago

Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says

MT Newswires Live
·
Yesterday

UBS Lifts AbbVie Target as Focus Expands Beyond Immunology Drugs

Reuters
·
Yesterday

1 Drugs Could Ease Back and Knee Pain, but Doctors Say There are Risks for Older Adults

Dow Jones
·
Yesterday

Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer Look

TIPRANKS
·
Yesterday

BofA Securities Adjusts Eli Lilly Price Target to $1,341 From $1,344, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Abbvie Inc. : UBS Raises Target Price to $275 from $260

THOMSON REUTERS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Yesterday

Merck & Company (MRK) Receives a Buy from UBS

TIPRANKS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Veeva Systems (VEEV) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
Yesterday

Analysts Have Conflicting Sentiments on These Healthcare Companies: Envista Holdings (NVST), Bristol-Myers Squibb (BMY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Yesterday

Johnson & Johnson reports new two-year results from Phase 3 ICONIC-LEAD study

TIPRANKS
·
Yesterday

J&J Says Phase 3 Iconic-LEAD Trial Shows Icotyde Sustains Plaque Psoriasis Clearance Through 2 Years

Reuters
·
Yesterday

J&J - at Week 112, 72% Achieve Pasi 90, 70% Achieve Iga 0/1 with Icotyde

THOMSON REUTERS
·
Yesterday

J&J - no New Safety Signals Identified for Icotyde Through Week 112

THOMSON REUTERS
·
Yesterday

New Johnson & Johnson Icotyde® (Icotrokinra) Long-Term Data Demonstrate Robust 2-Year Results in the Treatment of Adults and Adolescents with Plaque Psoriasis

THOMSON REUTERS
·
Yesterday

Eli Lilly announces new TOGETHER-PsO trial data

TIPRANKS
·
Yesterday
More